5.92

0.08% -0.02

Puma Biotechnology Inc (PBYI)

Overview News Price History Option Chain Financials Discussions Forecast

Puma Biotechnology Inc stock is traded at $5.92, with a volume of 25,308. It is down -0.08% in the last 24 hours and up +11.98% over the past month. Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Previous Close:

$5.94

Open:

$5.93

24h Volume:

25,308

Relative Volume:

0.05

Market Cap:

$298.32M

Revenue:

$230.47M

Net Income/Loss:

$30.28M

P/E Ratio:

9.7049

EPS:

0.61

Net Cash Flow:

$38.86M

1W Performance:

-1.25%

1M Performance:

+11.98%

6M Performance:

+65.78%

1Y Performance:

+67.18%

1-Day Range:

$5.82

$5.9551

1-Week Range:

$5.635

$6.05

52-Week Range:

$2.575

$6.27

Puma Biotechnology Inc Stock (PBYI) Company Profile

Name

Puma Biotechnology Inc

Sector

Healthcare (1119)

Industry

Biotechnology (624)

Phone

(424) 248-6500

Address

10880 WILSHIRE BLVD., LOS ANGELES, CA

Employee

172

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PBYI's Discussions on Twitter

Compare PBYI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PBYI Puma Biotechnology Inc	5.92	299.32M	230.47M	30.28M	38.86M	0.61
VRTX Vertex Pharmaceuticals Inc	466.70	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	780.49	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	393.09	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.04	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	174.03	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy
Jun-25-20	Resumed	BofA/Merrill	Underperform
Oct-08-19	Downgrade	Goldman	Neutral → Sell
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-10-19	Downgrade	Citigroup	Buy → Neutral
Jan-17-19	Initiated	Leerink Partners	Mkt Perform
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Sep-17-18	Initiated	Goldman	Sell
May-11-18	Reiterated	Stifel	Buy
Nov-10-17	Reiterated	Citigroup	Buy
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform
Oct-02-17	Reiterated	Stifel	Buy
Sep-11-17	Reiterated	Credit Suisse	Outperform
Jul-10-17	Resumed	Leerink Partners	Outperform
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform
Mar-02-17	Reiterated	RBC Capital Mkts	Sector Perform

View All

Puma Biotechnology Inc Stock (PBYI) Latest News

Dec 31, 2025

Up 91% in the Past Year, Is This Biotech Stock Red Hot or a Red Flag? - Barchart.com

Dec 31, 2025

Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200 Day Moving AverageHere's What Happened - MarketBeat

Dec 31, 2025

Dec 24, 2025

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference - sharewise.com

Dec 24, 2025

Dec 23, 2025

Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI) - BioSpace

Dec 23, 2025

Dec 22, 2025

Puma Biotechnology Added to Nasdaq Biotechnology Index - marketscreener.com

Dec 22, 2025

Dec 21, 2025

If EPS Growth Is Important To You, Puma Biotechnology (NASDAQ:PBYI) Presents An Opportunity - Yahoo Finance

Dec 21, 2025

Dec 20, 2025

How Puma Biotechnology Inc. stock reacts to oil pricesPortfolio Value Report & Low Risk High Reward Trade Ideas - Улправда

Dec 20, 2025

What dividend safety score for Puma Biotechnology Inc. stockJuly 2025 Momentum & Long-Term Growth Portfolio Plans - Улправда

Dec 20, 2025

Dec 19, 2025

What analyst consensus says on Puma Biotechnology Inc. stock2025 Buyback Activity & Expert Curated Trade Setups - Улправда

Dec 19, 2025

History Review: How Puma Biotechnology Inc. stock reacts to oil pricesWeekly Risk Report & AI Driven Stock Reports - Улправда

Dec 19, 2025

Will Puma Biotechnology Inc. stock keep outperforming rivals2025 Buyback Activity & Daily Entry Point Alerts - DonanımHaber

Dec 19, 2025

Dec 17, 2025

CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy? - TradingView — Track All Markets

Dec 17, 2025

Dec 16, 2025

Why analysts upgrade Puma Biotechnology Inc stock2025 Winners & Losers & Consistent Income Trade Ideas - moha.gov.vn

Dec 16, 2025

Dec 15, 2025

Puma Biotechnology Earnings Notes - Trefis

Dec 15, 2025

Dec 13, 2025

Acorn Capital Advisors LLC Has $14.17 Million Stake in Puma Biotechnology, Inc. $PBYI - MarketBeat

Dec 13, 2025

Dec 09, 2025

With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case - Sahm

Dec 09, 2025

Dec 08, 2025

American Century Companies Inc. Grows Stake in Puma Biotechnology, Inc. $PBYI - MarketBeat

Dec 08, 2025

Dec 06, 2025

What analysts say about Puma Biotechnology Inc stockStock Liquidity Analysis & Minimal Investment Capital Gains - earlytimes.in

Dec 06, 2025

Can Puma Biotechnology Stock Hold Up When Markets Turn? - Trefis

Dec 06, 2025

Dec 04, 2025

What insider trading reveals about Puma Biotechnology Inc. stock2025 Top Gainers & Daily Oversold Bounce Ideas - Newser

Dec 04, 2025

Dec 02, 2025

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com

Dec 02, 2025

Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat

Dec 02, 2025

Nov 30, 2025

With 60% ownership of the shares, Puma Biotechnology, Inc. (NASDAQ:PBYI) is heavily dominated by institutional owners - Yahoo Finance

Nov 30, 2025

Nov 29, 2025